Quarterly ResultMay 11, 2026, 04:07 PM
Coherus Q1 Net Revenue $12.3M; Net Loss $(36.9)M
AI Summary
Coherus Oncology reported Q1 2026 net revenue from continuing operations of $12.3 million, an increase from $7.6 million in Q1 2025. LOQTORZI net revenue was $11.8 million, up 61% year-over-year but down 5% quarter-over-quarter due to seasonal factors. The company posted a net loss from continuing operations of $(36.9) million, or $(0.27) per share, an improvement from $(47.4) million in the prior year. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities, and completed patient accrual for the 1L HCC Phase 2 trial of casdozokitug, with data expected mid-year.
Key Highlights
- Q1 2026 net revenue from continuing operations was $12.3 million, up from $7.6 million YoY.
- LOQTORZI net revenue reached $11.8 million in Q1 2026, a 61% increase YoY.
- Net loss from continuing operations was $(36.9) million, or $(0.27) per share.
- Cash, cash equivalents, and marketable securities totaled $167.0 million at quarter-end.
- R&D expenses decreased to $21.5 million from $24.4 million in Q1 2025.
- SG&A expenses decreased to $23.1 million from $26.0 million in Q1 2025.
- Patient accrual completed for 1L HCC Phase 2 trial of casdozokitug, data expected mid-2026.
- Public offering generated $53.6 million net from 32.89 million shares of common stock.